Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Key Terms

next-generation sequencing medical

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

ngs medical

A laboratory method that reads large amounts of DNA or RNA quickly to identify genetic differences, mutations, or microbes, similar to scanning many pages of a book at once to find important words. Investors care because it drives diagnostics, drug discovery and personalized treatments, can create recurring revenue from testing services and instruments, and influences regulatory approvals, partnerships and market value in biotech and healthcare companies.

homologous recombination deficiency medical

A condition in which a cell’s ability to fix certain types of DNA damage is impaired, like a zipper that can’t close properly after being pulled apart. Investors care because tumors with this flaw are often more sensitive to specific drugs and diagnostic tests, making related treatments, companion diagnostics, and clinical trial results potentially decisive for a company’s drug value and future revenue.

real-world data medical

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

nsclc medical

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

minimal residual disease medical

Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.

mrd medical

MRD stands for minimal residual disease, the tiny number of cancer cells that can remain in the body after treatment and that may not show up on routine scans. Detecting MRD is like finding a few seeds left in a garden after clearing: it helps doctors predict the chance of relapse and measure how effective a therapy is, which investors watch because MRD results can influence clinical trial success, regulatory decisions, and a drug’s market potential.

circulating tumor dna medical

Fragments of DNA shed by cancer cells into the bloodstream that act like tiny fingerprints of a tumor; they can be detected with a blood test rather than a biopsy. Investors care because circulating tumor DNA (ctDNA) enables faster, lower-cost ways to detect disease, track treatment response, identify emerging resistance and enroll patients in trials—factors that can materially affect the commercial prospects of diagnostics and therapeutics.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 29 - June 3, 2026 in Chicago, Illinois.

“This year’s ASCO Annual Meeting marks a significant milestone for Tempus, as we are presenting our largest collection of accepted research to date, further underscoring the critical role that multimodal data and AI-driven insights play in advancing precision medicine across oncology,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “The breadth of our findings demonstrates the tangible impact of these tools in transforming complex real-world data into actionable evidence, helping more patients benefit from the next generation of innovative therapies.”

Research highlights include:

Saturday, May 30, 2026
9:00am - 12:00pm CT

Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success
Poster Board: 536; Abstract Number: 1618

AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.
Poster Board: 193; Abstract Number: 4210

1:30 pm – 4:30 pm CT

ESR1 mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard of care hormonal therapy
Poster Board: 199; Abstract Number: 3062

First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF-mutated differentiated thyroid cancer (DTC): Insights from real-world data.
Poster Board: 509; Abstract Number: 6052

Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors
Poster Board: 219; Abstract Number: 3082

Sunday, May 31, 2026
9:00am - 12:00pm CT

Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve early-stage NSCLC biomarker testing
Poster Board: 518; Abstract Number: 8044

Monday, June 1, 2026
9:00 am - 12:00 pm CT

Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome
Poster Board: 363; Abstract Number: 6570

1:30 pm - 4:30 pm CT

GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies
Poster Board: 130b; Abstract Number: TPS649

Explore the full scope of Tempus-authored research and discover how the company is advancing precision medicine at the 2026 ASCO Annual Meeting here.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526086558/en/

Tempus
Hanah Heintzelman
Hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.